scholarly journals Exhaled Biomarkers in Idiopathic Pulmonary Fibrosis—A Six-Month Follow-up Study in Patients Treated with Pirfenidone

2020 ◽  
Vol 9 (8) ◽  
pp. 2523
Author(s):  
Kaja Jaskiewicz ◽  
Katarzyna Mycroft ◽  
Marta Maskey-Warzechowska ◽  
Karolina Paralusz ◽  
Natalia Siemiez ◽  
...  
Keyword(s):  
Idiopathic Pulmonary Fibrosis ◽  
Pulmonary Fibrosis ◽  
Exhaled Breath Condensate ◽  
High Sensitivity ◽  
Cytokine Profile ◽  
Exhaled Breath ◽  
Vascular Endothelial ◽  
Tnf Α ◽  
Cytokine Levels ◽  
Endothelial Growth Factor

The mechanism of action of pirfenidone in idiopathic pulmonary fibrosis (IPF) has not been fully elucidated. To offer additional insight, we evaluated the change in the cytokine profile in exhaled breath condensate (EBC) following a six-month treatment with pirfenidone in patients with IPF. EBC concentrations of interleukin (IL)-6, IL-8, IL-15, TNF-α and VEGF-A were assessed with ELISA and compared at baseline and after six months of pirfenidone treatment. Twenty-nine patients with IPF and 13 controls were evaluated at baseline. With the exception of IL-8 concentration, which was lower in patients with IPF when compared to controls (p = 0.005), the cytokine levels did not differ between the groups. Despite the use of a high sensitivity assay, IL-8 reached detectable values only in 24% of IPF patients. EBC analysis after six months of treatment with pirfenidone did not reveal any differences in the cytokine levels. The change in EBC vascular endothelial growth factor A (VEGF-A) correlated with the change in the 6 min walk distance (r = 0.54, p = 0.045). We conclude that a six-month treatment with pirfenidone did not significantly change the EBC cytokine profile. Our findings support the potential usefulness of VEGF-A as a marker in IPF. The low EBC IL-8 level in patients with IPF is a novel finding which needs confirmation in larger studies.

Epithelial alarmin levels in exhaled breath condensate in patients with idiopathic pulmonary fibrosis

2018 ◽  
Author(s):  
Sebastian Majewski ◽  
Damian Tworek ◽  
Karolina Szewczyk ◽  
Zofia Kurmanowska ◽  
Adam Antczak ◽  
...  
Keyword(s):  
Idiopathic Pulmonary Fibrosis ◽  
Pulmonary Fibrosis ◽  
Exhaled Breath Condensate ◽  
Exhaled Breath ◽  
Breath Condensate

scholarly journals Nintedanib (BIBF 1120) for IPF: a tomorrow therapy?

2012 ◽  
Vol 7 ◽  
Author(s):  
Sabina A. Antoniu
Keyword(s):  
Growth Factor ◽  
Idiopathic Pulmonary Fibrosis ◽  
Pulmonary Fibrosis ◽  
Platelet Derived Growth Factor ◽  
Vascular Endothelial ◽  
Life Threatening ◽  
Endothelial Growth Factor ◽  
Potential Use ◽  
Existing Data ◽  
Bibf 1120

Idiopathic pulmonary fibrosis is a rare, life threatening disease characterized by an anarchic fibrogenesis, limited survival and few therapeutic options. Its pathogenesis is complex and involves the interaction among various pathways driven by proinflammatory/profibrogenetic mediators such as platelet -derived growth factor, vascular endothelial growth factor or basic fibroblast growth factor. Given their prominent pathogenic roles in this disease such growth factor might be suitable therapeutic targets.In fact, the existing preclinical and clinical data demonstrated that their therapeutic inhibition results in a delayed progression of the pulmonary fibrosis and in the improvement of the disease outcome. BIBF 1120 is a potent triple blocker of the receptors of these growth factors which is currently evaluated as a potential therapy in the idiopathic pulmonary fibrosis. This review discusses the existing data supporting its potential use in this disease.

scholarly journals Exhaled breath condensate as a potential biomarker tool for idiopathic pulmonary fibrosis—a pilot study

2017 ◽  
Vol 12 (1) ◽  
pp. 016003 ◽  
Author(s):  
Barbara Rindlisbacher ◽  
Carina Strebel ◽  
Sabina Guler ◽  
Attila Kollár ◽  
Thomas Geiser ◽  
...  
Keyword(s):  
Pilot Study ◽  
Idiopathic Pulmonary Fibrosis ◽  
Pulmonary Fibrosis ◽  
Exhaled Breath Condensate ◽  
Exhaled Breath ◽  
Potential Biomarker ◽  
Breath Condensate

scholarly journals Epithelial Alarmins in Serum and Exhaled Breath in Patients with Idiopathic Pulmonary Fibrosis: A Prospective One-Year Follow-Up Cohort Study

2019 ◽  
Vol 8 (10) ◽  
pp. 1590 ◽  
Author(s):  
Majewski ◽  
Szewczyk ◽  
Białas ◽  
Miłkowska-Dymanowska ◽  
Górski ◽  
...  
Keyword(s):  
Idiopathic Pulmonary Fibrosis ◽  
Pulmonary Fibrosis ◽  
Exhaled Breath Condensate ◽  
Exhaled Breath ◽  
Antifibrotic Therapy ◽  
Lung Compartment ◽  
Before And After ◽  
One Year ◽  
Study Participants

Background: Recently, epithelial alarmins have been shown to play important roles in non-allergen driven respiratory diseases like idiopathic pulmonary fibrosis (IPF). Little is known about the expression of the epithelial alarmins in IPF. Methods: This study aimed to prospectively examine interleukin (IL)-25, IL-33, and thymic stromal lymphopoietin (TSLP) levels in the serum and exhaled breath condensate (EBC) in patients with IPF before and after one-year of antifibrotic treatment. A total of 82 volunteers, including 52 patients diagnosed with IPF that qualified for antifibrotic therapy as well as 30 controls, were examined. All study participants underwent baseline peripheral blood and EBC sampling. In 35 out of 52 IPF subjects, a follow-up sampling was performed after 12 months of antifibrotic treatment. Concentrations of alarmins in the serum and EBC were evaluated by means of ELISA. Results: Baseline TSLP concentrations were significantly elevated in patients with IPF compared to controls both in the serum (p < 0.05) and EBC (p < 0.0001). Baseline IL-25 and IL-33 serum and EBC levels did not differ significantly between IPF subjects and controls. Prospective analysis of changes in the epithelial alarmin levels showed significantly decreased IL-25 and TSLP EBC concentrations after 12 months of antifibrotic treatment (p < 0.05), which was observed in the subgroup of IPF patients treated with pirfenidone, but not in those treated with nintedanib. In stable patients with IPF over a study period (absolute forced vital capacity (FVC) % of predicted decline/year ≤ 5%, n = 25), a significant decrease in the EBC levels of both IL-25 and TSLP after 12 months of antifibrotic treatment was noted (p < 0.05), whereas, in progressor IPF patients (absolute FVC % of predicted decline/year > 5%, n = 10), a significant decrease was noted in the IL-25 EBC levels only (p < 0.05). Conclusions: Elevated TSLP levels in patients with IPF and their significant decrease in the lung compartment during antifibrotic therapy in stable patients with IPF, but not in progressors, support its significant contribution to pro-fibrotic type 2 immune responses in IPF. Noted changes in the epithelial alarmins concentration in the lung compartment during pirfenidone therapy may suggest its possible interaction with epithelial alarmins pathways in IPF.

scholarly journals Nitrite in exhaled breath condensate as a marker of nitrossative stress in the airways of patients with asthma, COPD, and idiopathic pulmonary fibrosis

2010 ◽  
Vol 24 (5) ◽  
pp. 317-322 ◽  
Author(s):  
Vladimír Rihák ◽  
Petr Zatloukal ◽  
Jirina Chládková ◽  
Alena Zimulová ◽  
Zuzana Havlínová ◽  
...  
Keyword(s):  
Idiopathic Pulmonary Fibrosis ◽  
Pulmonary Fibrosis ◽  
Exhaled Breath Condensate ◽  
Exhaled Breath ◽  
Breath Condensate

scholarly journals Low Systemic Levels of Chemokine C-C Motif Ligand 3 (CCL3) are Associated with a High Risk of Venous Thromboembolism in Patients with Glioma

Cancers ◽  
2019 ◽  
Vol 11 (12) ◽  
pp. 2020 ◽  
Author(s):  
Pegah Mir Seyed Nazari ◽  
Christine Marosi ◽  
Florian Moik ◽  
Julia Riedl ◽  
Öykü Özer ◽  
...  
Keyword(s):  
Venous Thromboembolism ◽  
Serum Levels ◽  
Vascular Endothelial ◽  
Serum Samples ◽  
Blood Draw ◽  
Potential Biomarker ◽  
Increased Risk ◽  
Tnf Α ◽  
Cytokine Levels ◽  
Endothelial Growth Factor

A tight interplay between inflammation and hemostasis has been described as a potential driver for developing venous thromboembolism (VTE). Here, we investigated the association of systemic cytokine levels and risk of VTE in patients with glioma. This analysis was conducted within the prospective, observational Vienna Cancer and Thrombosis Study. Patients with glioma were included at time of diagnosis or progression and were observed for a maximum of two years. Primary endpoint was objectively confirmed VTE. At study entry, a single blood draw was performed. A panel of nine cytokines was measured in serum samples with the xMAP technology developed by Luminex. Results: Overall, 76 glioma patients were included in this analysis, and 10 (13.2%) of them developed VTE during the follow-up. Chemokine C-C motif ligand 3 (CCL3) levels were inversely associated with risk of VTE (hazard ratio [HR] per double increase, 95% confidence interval [CI]: 0.385, 95% CI: 0.161–0.925, p = 0.033), while there was no association between the risk of VTE and serum levels of interleukin (IL)-1β, IL-4, IL-6, IL-8, IL-10, IL-11, tumor necrosis factor (TNF)-α and vascular endothelial growth factor (VEGF), respectively. In conclusion, low serum levels of CCL3 were associated with an increased risk of VTE. CCL3 might serve as a potential biomarker to predict VTE risk in patients with glioma.

Sign in / Sign up

Export Citation Format

Share Document